Clinico-Pathologic-Genetic-Imaging Stud… | Clinical Trial

Key information

Conditions

PSP Aphasia Apraxia of Speech Apraxias Autonomic Nervous System Diseases Basal Ganglia Diseases Behavioral Variant of Frontotemporal Dementia Brain Diseases CBD Cardiovascular Diseases Central Nervous System Diseases Communication Disorders Dementia FTD Frontotemporal Dementia Frontotemporal Lobar Degeneration Hypotension LPA Language Disorders MSA - Multiple System Atrophy Mental Disorders Metabolic Diseases Movement Disorders Multiple System Atrophy Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Nutritional and Metabolic Diseases PCA PPA Parkinson Disease Parkinsonian Disorders Pathological Conditions, Signs and Symptoms Pick Disease of the Brain Primary Dysautonomias Proteostasis Deficiencies Psychomotor Disorders Semantic Aphasia Semantic Dementia Shy-Drager Syndrome Signs and Symptoms Speech Disorders Synucleinopathies TDP-43 Proteinopathies Vascular Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

About this study

The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan and/or a C-11 ER176 PET/CT scan. All participants will be asked to provide a blood sample to allow for future genetic studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All participants will be over the age of 21
Have symptoms suggestive of a neurodegenerative and/or related disorder

Exclusion criteria

Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes
Women that are pregnant or post-partum and breast-feeding will be excluded
Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome
Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts)
Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)

Treatment and study plan

C-11 PiB

Drug

Completing PET scan looking for amyloid protein

AV1451 Tau

Drug

Completing PET scan looking for tau protein

C-11 ER176

Drug

Completing PET scan looking for neuroinflammation

Primary outcomes

Imaging analysis

Time frame: 1 year

Longitudinal images and correlates will be measured and tracked to determine direct correlations in the brain with disease progression on a yearly basis

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Acronym: AND1

Important dates

Study start: 2020
Primary completion: 2050
Study completion: 2050
First posted: Dec 22, 2020
Registry last updated: Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting